Navigating HIV-1 drug resistance: A comprehensive review of protease inhibitor efficacy and mutation dynamics [0.03%]
HIV-1耐药的应对策略——蛋白酶抑制剂疗效及其突变动态综述
Kaile Yang,Xiurong Sun,Junbing Chen et al.
Kaile Yang et al.
HIV type 1 (HIV-1) poses a significant threat to global public health. Protease, a critical enzyme in the HIV-1 life cycle, has long been regarded as an important therapeutic target. However, the emergence of drug resistance mutations enabl...
Targeting nuclear elements to reverse epigenetic dysregulation in the tumor microenvironment: a key to epigenome-directed cancer immunotherapy [0.03%]
靶向核元件以逆转肿瘤微环境中的表观遗传失调：表观基因组导向癌症免疫治疗的关键
Rebanta Roy,Priyanka Bhadra,Dwaypayan Ghosh et al.
Rebanta Roy et al.
Reactivation of the immune response is one of the most significant goals in modern cancer therapy. In addition to genetic mutations and other key factors, epigenetics play an important role in immune evasion by cancer cells. We examine the ...
Yasmine Ferchichi,Àngela Natividad,Rubén Artero et al.
Yasmine Ferchichi et al.
Over the past few years, therapeutic development for myotonic dystrophy type 1 has accelerated markedly, with ongoing clinical trials nearly doubling and several candidates advancing to late-stage evaluation. Approaches have diversified, in...
Anas Alhafi,Vivek Gupta
Anas Alhafi
Oral delivery remains one of the most challenging objectives in proteolysis-targeting chimera (PROTAC) development. Although a growing number of PROTACs are administered orally in clinical studies, and several have demonstrated measurable s...
If GLP-1s are "longevity drugs," the evidence bar must change-carefully [0.03%]
如果GLP-1类药物是“长寿药”，那么证据门槛必须谨慎改变
Charles H Jones,Mikael Dolsten
Charles H Jones
Dermal PBPK modeling in the era of model-informed drug development: Strategies, innovations, and regulatory impact [0.03%]
模型指导下的药物研发时代下的经皮给药PBPK建模：策略、创新和监管影响
Heta Shah,Aniruddha Banerjee,Anagha Damre
Heta Shah
Dermal drug delivery has emerged as an alternative to conventional routes of drug administration owing to its non-invasive nature and improved patient compliance. Dermal physiologically based pharmacokinetic (PBPK) modeling integrates skin ...
Where do we go from here? Current state of drug-target binding kinetics and a roadmap to their establishment in drug discovery campaigns [0.03%]
从这里我们何去何从？药物-靶点结合动力学现状及其在新药研发中的应用路线图展望
Steffen Wolf,Giovanni Bottegoni,Ariane Nunes-Alves et al.
Steffen Wolf et al.
Because of the observation that kinetic rates can be better correlated with in vivo drug efficacy than simple affinities, significant efforts have been made to develop experimental and computational methods to predict drug-target residence ...
Trimethylamine-N-oxide (TMAO) in multiorgan disease: mechanisms, translational insights, and therapeutic opportunities [0.03%]
胆碱代谢产物TMAO与多器官疾病：机制、转化研究进展及治疗策略
Venkata Subrahmanya Kumar Samanthapudi,Keila Carolina Ostos Mendoza,Sahithi Puvvala et al.
Venkata Subrahmanya Kumar Samanthapudi et al.
Trimethylamine-N-oxide (TMAO), a gut microbe-derived metabolite, acts as a key mediator linking diet, microbial metabolism, and disease across multiple organs. Beyond cardiovascular and metabolic disorders, TMAO has also been implicated in ...
Farhan Mazahir
Farhan Mazahir
Micro/nanomotors show exceptional applications, such as thrombus ablation, biofilm eradication, diagnosis, and bioimaging. In addition, stimulus-driven advances in micro/nanomotor design enable controlled guidance, improved speed and direct...
The evolving role of China in global clinical trials: from late-stage add-on to strategic early inclusion [0.03%]
中国在全球临床试验中的作用演变：从后期补充到早期战略性纳入
Ju Wang,Siyu Lan,Jun Li et al.
Ju Wang et al.
China is increasingly being considered for earlier inclusion in multi-regional clinical trials (MRCTs), driven by improved regulatory predictability, enhanced operational delivery, and greater outward-facing development activity. However, e...